JAHA:接受蒽环类化疗的儿童和年轻成人心脏毒性的潜在标志物

2017-04-05 xing.T MedSci原创

在这个研究中,ACs治疗后会出现心脏相关的血浆miRNA失调。AC治疗后血浆中miR-29b和miR-499会急性升高,并可以观察到蒽环类药物剂量和心肌损伤标志物存在量效关系。进一步评估miRNAs可能为AC诱导的心脏毒性的机制提供了新视角,并得到通过早期干预来减轻心脏毒性的生物标志物。

通过生物标志物对蒽环类药物(AC)诱导心脏毒性的早期检测,可能实现在不可逆的损伤发生前对心肌进行保护性干预。循环中MicroRNAs(miRNAs)是有前景的血管疾病生物学标志物,然而,miRNAs在AC诱导的心脏毒性中的作用尚未被研究。本研究旨在确定AC诱导的儿童血浆中miRNA表达变化,以及其表达与心脏损伤标志物的相关性。

研究人员分析了33个分别接受AC治疗(n=24)和非心脏毒性化疗(n=9)儿童治疗前后血浆中24个候选miRNAs 的表达谱。研究人员确定了每个处理组治疗前后不同时间间隔(6、12和24小时)miRNAs的 相对变化,并且将各个组进行了比较。研究人员进一步探究了血浆中miRNAs 的表达与AC剂量和高灵敏度肌钙蛋白T之间的关系。

研究人员发现相比于那些接受非心脏毒性的患者,接受蒽环类化疗的患者候选的心脏相关血浆miRNAs 出现更严重的化疗诱导失调(24小时MANOVA;P=0.024)。具体来说,血浆中miRs-29b和miRs-499在AC处理后6至24小时期间上调,并且其化疗后的表达与AC的剂量明显相关。急性心肌损伤患者(高灵敏度肌钙蛋白T从基线增加≥5ng/L)AC处理后表现出miR-29b和miR-499表达升高,相比于那些没有发生急性心肌损伤的患者。

在这个研究中,ACs治疗后会出现心脏相关的血浆miRNA失调。AC治疗后血浆中miR-29b和miR-499会急性升高,并可以观察到蒽环类药物剂量和心肌损伤标志物存在量效关系。进一步评估miRNAs可能为AC诱导的心脏毒性的机制提供了新视角,并得到通过早期干预来减轻心脏毒性的生物标志物。

原始出处:


Kasey J. Leger,et al. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.JAHA.2017. https://doi.org/10.1161/JAHA.116.004653

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=322924, encodeId=0308322924a1, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jun 10 06:23:48 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840988, encodeId=8a6c1840988c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 02 15:32:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267412, encodeId=1b8d126e412ed, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521687, encodeId=7076152168e38, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
    2018-06-10 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=322924, encodeId=0308322924a1, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jun 10 06:23:48 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840988, encodeId=8a6c1840988c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 02 15:32:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267412, encodeId=1b8d126e412ed, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521687, encodeId=7076152168e38, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=322924, encodeId=0308322924a1, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jun 10 06:23:48 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840988, encodeId=8a6c1840988c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 02 15:32:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267412, encodeId=1b8d126e412ed, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521687, encodeId=7076152168e38, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
    2017-04-07 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=322924, encodeId=0308322924a1, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Jun 10 06:23:48 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840988, encodeId=8a6c1840988c4, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 02 15:32:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267412, encodeId=1b8d126e412ed, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521687, encodeId=7076152168e38, content=<a href='/topic/show?id=a59d88340d2' target=_blank style='color:#2F92EE;'>#蒽环类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88340, encryptionId=a59d88340d2, topicName=蒽环类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=97d111387900, createdName=shijzhiewnjhch, createdTime=Fri Apr 07 06:32:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]

相关资讯

蒽环类药物心脏毒性保护剂临床应用的热点问题

蒽环类药物心脏毒性保护剂临床应用的热点问题

Ann Onco:FOXP3表达示蒽环类抗乳腺癌效果

  法国学者3月19日在线发表于《肿瘤学年鉴》(Annals of Oncology)的一项研究表明,乳腺癌细胞POXP3表达状态可能可以精确预测蒽环类抗乳腺癌效果。   该研究显示,乳腺癌细胞表达FOXP3与较好的总生存(OS)状况相关(P=0.003)。   单变量和多变量分析显示,乳腺癌细胞表达FOXP3与接受蒽环类为基础辅助化疗而非蒽环类-紫杉烷序贯化疗的患者较好的OS状态具有独立相关

JNCI:蒽环类与曲妥珠单抗带来心脏衰竭风险

    临床试验结果已经显示,乳腺癌患者接受蒽环类和曲妥珠单抗(赫赛汀,罗氏)的治疗会增加心力衰竭和心肌病的风险。但是在临床试验之外的患者人群中,治疗与风险的关系是怎样?一项研究结果表明:在“现实世界”的观察性队列研究能够表明这样的风险可能会更高。该研究发表于8月31日美国国家癌症研究所杂志。     中位随访时间比之前的临床试验延长了

蒽环类药物心脏毒性防治共识

蒽环类药物心脏毒性防治共识